(Q34481755)

2 August 2017

1 reference

title

Antiglucocorticoid drugs in the treatment of depression (English)

1 reference

2 August 2017

2

Wolkowitz OM

1 reference

2 August 2017

Reus VI

1

1 reference

PubMed ID

11772285

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

1789-1796

1 reference

2 August 2017

10

1 reference

Treatment of depression with antiglucocorticoid drugs

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Glucocorticoid medication, memory and steroid psychosis in medical illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Metyrapone displays antidepressant-like properties in preclinical paradigms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

5-HT-HPA interactions in two models of transgenic mice relevant to major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Functional effects of corticosterone on 5-HT(1A) and 5-HT(1B) receptor activity in rat brain: in vivo microdialysis studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Central 5-hydroxytryptamine-2A receptor expression in transgenic mice bearing a glucocorticoid receptor antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Corticosteroids in relation to fear, anxiety and psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Stress hormone-related psychopathology: pathophysiological and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Effects of adverse experiences for brain structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Regulation of ischemic cell death by glucocorticoids and adrenocorticotropic hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The neurobiology of stress: from serendipity to clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Neuropeptides and the hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The dexamethasone suppression test and suicide prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Future therapeutic targets in mood disorders: the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The brain mineralocorticoid receptor: greedy for ligand, mysterious in function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Glucocorticoid and mineralocorticoid receptors are involved in the facilitation of anxiety-like response induced by restraint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Stress and cognition: are corticosteroids good or bad guys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

A molecular and cellular theory of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Down-regulation of BDNF mRNA, with no effect on trkB or glucocorticoid receptor m RNAs, in the porcine hippocampus after acute dexamethasone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Modulation of glucocorticoid receptor gene expression by antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Treatment of major depression with steroid suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Ketoconazole administration in hypercortisolemic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Aminoglutethimide, a corticosteroid synthesis inhibitor, facilitates brain stimulation reward in food-restricted rats: an investigation of underlying mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Neuroendocrine responses to inhibitors of steroid biosynthesis in patients with major depression resistant to antidepressant therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.10.1789

10.1517/13543784.10.10.1789

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11772285